Individuals without private health insurance coverage are more likely to be diagnosed with late-stage cancer and have worse survival, according to a study published online July 13 in CA: A Cancer Journal for Clinicians.
Jul 13, 2022
0
6
Immunotherapy has revolutionized treatment for many forms of cancer, but glioblastoma multiforme (GBM), the most common and deadly form of brain cancer, has remained untouched. GBM tumors are sometimes referred to as "cold"—that ...
Jul 11, 2022
0
59
New research from UVA Cancer Center and UVA Children's Hospital could be a "game-changer" in the treatment of a pair of deadly brain tumors, and the discovery could lead to better treatments for other solid tumors as well.
Jul 11, 2022
0
815
When words fail, gestures can help to get the message across—especially for people who have a language disorder. An international research team has now shown that listeners attend the gestures of people with aphasia more ...
Jul 7, 2022
0
6
A therapy that uses a virus to kill tumor cells can be safely given to children with a rare, incurable form of brain cancer, an early study has found.
Jun 30, 2022
0
8
Tumors are made up of many types of cells, both cancerous and benign. The specific complexity of the cells inside brain tumors has been a trademark of the disease, one that makes treatment extremely difficult. While scientists ...
Jun 28, 2022
0
121
The classification of brain tumors—and thus the choice of optimal treatment options—can become more accurate and precise through the use of artificial intelligence in combination with physiological imaging. This is the ...
Jun 21, 2022
0
294
A drug carrier able to reach the brain, bind to an aggressive type of tumor called glioblastoma multiforme, and release a chemotherapeutic agent has been tested for the first time by Brazilian researchers. According to an ...
Jun 14, 2022
0
34
A protein that the body naturally produces could become an important new immunotherapy drug in the cache of cancer-fighting tools available to oncologists. UC Davis cancer researchers for both companion dogs and humans joined ...
Jun 9, 2022
0
41
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions ...
Jun 3, 2022
0
2
